Xie Bing resigned as CEO of China biopharmaceutical Co., Ltd. and was transferred to senior vice chairman of the board of directors with effect from the previous day (19th). Xie Bing will remain as executive director and member of the Executive Board Committee and Nomination Committee of the company. On the same day, Li Yi, formerly Chairman of JPMorgan securities (China), was appointed as executive director and CEO of the company, Effective from the last day (19th). At present, the Hang Seng index is down 467 points or 1.86% at 24711 points, with the main board trading at 35.265 billion yuan. The state-owned enterprise index is down 184 points or 1.79% at 10128 points.